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Abstract
Purpose Metformin use has been associated with
decreased cancer risks, though data on esophageal cancer
are scarce. We explored the relation between use of met-
formin or other anti-diabetic drugs and the risk of esoph-
ageal cancer.
Methods We conducted a case–control analysis in the UK-
based general practice research database (GPRD, now clinical
practice research datalink, CPRD). Cases were individuals
with an incident diagnosis of esophageal cancer between 1994
and 2010 at age 40–89 years. Ten controls per case were
matched on age, sex, calendar time, general practice, and
number of years of active history in the GPRD prior to the
index date. Various potential confounders including diabetes
mellitus, gastro-esophageal reflux, and use of proton-pump
inhibitors were evaluated in univariate models, and the final
results were adjusted for BMI and smoking. Results are pre-
sented as odds ratios (ORs) with 95 % confidence intervals
(CI).
Results Long-term use (C30 prescriptions) of metformin
was not associated with a materially altered risk of esoph-
ageal cancer (adj. OR 1.23, 95 % CI 0.92–1.65), nor was
long-term use of sulfonylureas (adj. OR 0.93, 95 % CI
0.70–1.23), insulin (adj. OR 0.87, 95 % CI 0.60–1.25), or of
thiazolidinediones (adj. OR 0.71, 95 % CI 0.37–1.36).
Conclusion In our population-based study, use of met-
formin was not associated with an altered risk of esopha-
geal cancer.
Keywords Esophageal cancer  Anti-diabetic drugs 
Epidemiology  Case–control analysis  Metformin
Introduction
Worldwide, more than 400,000 incident esophageal cancer
cases and almost as many deaths occurred in 2008 [1].
Within the last decades, a sharp increase in the incidence of
esophageal adenocarcinoma has been reported in the US [2]
as well as in several European countries [3–5]. At the same
time, the prevalence of obesity and diabetes has been
increasing [6–9]. Obesity has been identified as a major risk
factor for adenocarcinoma of the esophagus [10, 11].
Additionally, diabetes has been associated with an increased
risk for several cancer entities [12]. However, data for
esophageal cancer risk in diabetes patients have been
inconsistent. In a recent study, men with diabetes mellitus
had a statistically significantly decreased risk for cancer of
the esophagus (relative risk, RR, 0.77, 95 % CI 0.72–0.82)
[13]. The decrease was mainly driven by the effect in black
men (RR 0.54, 95 % CI 0.48–0.60). In an earlier study,
diabetes was associated with an increased risk of esophageal
adenocarcinoma (adj. OR 1.59, 95 % CI 1.04–2.43), though
the risk was attenuated after further adjusting for body mass
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index (BMI) (adj. OR 1.32, 95 % CI 0.85–2.05) [14].
Another study analyzing cases of esophageal adenocarci-
noma which was based on interview-derived information on
comorbid medical conditions found a nonsignificantly
increased risk associated with a previous diabetes diagnosis
with no trend for diabetes duration [15]. Furthermore, a
case–control study found the risk of esophageal cancer to be
unaffected by a previous diabetes diagnosis (OR 1.1, 95 %
CI 0.8–1.5) [16]. In a recent meta-analysis encompassing 17
studies, the summary relative risk (SRR) for esophageal
cancer was 1.30 (95 % CI 1.12–1.50) in diabetic individu-
als, and the SRR for esophageal adenocarcinoma specifi-
cally was 2.12 (95 % CI 1.01–4.46) [17].
Anti-diabetic drugs have also been shown to affect cancer
risk, and long-term metformin use has been associated with
reduced risks for some cancer types and for cancer overall
[18–21]. So far, the association between metformin use and
esophageal carcinoma in particular has only been explored in
one recent observational study [22]. In this study, results varied
according to the covariates included in the model, and only 27
patients with cancer of the esophagus were studied. In a study of
patients with esophageal adenocarcinoma where all patients
were receiving neoadjuvant chemoradiation therapy, addi-
tional metformin use was associated with an increased response
rate compared to nonusers of metformin [23]. The pathologic
complete response rate was significantly higher in patients with
C150 mg of metformin per day compared to patients taking
\150 mg/day. Metformin also inhibited the growth of three
esophageal cancer cell lines in an in vitro study [24].
The potential mechanisms by which metformin may exert
anti-proliferative activities are not fully understood. Met-
formin decreases insulin resistance and lowers circulating
insulin levels by activating AMP-activated protein kinase
(AMPK), leading to decreased hepatic gluconeogenesis and
increased uptake of glucose in muscle [25]. Since some
cancer entities seem to proliferate more aggressively in a
high insulin environment, metformin could be beneficial in
slowing down cancer growth [26]. Additionally, metformin
has been shown to act as a direct tumor growth inhibitor, at
least in part by up-regulation of AMPK activity and by
downstream suppression of signaling through the mamma-
lian target of rapamycin (mTOR) [27].
The objective of our study was to assess esophageal
cancer risk in users of anti-diabetic drugs and compare
them to individuals with no exposure to these drugs.
Methods
Data source
We performed a retrospective case–control analysis using
data from the general practice research database (GPRD,
since March 2012 part of the data services provision from
clinical practice research datalink, CPRD [28]). The GPRD
provides health care information on some seven million
patients in the UK and has been previously described in
detail [29, 30]. General practitioners (GPs) record infor-
mation on demographics, diagnoses, and drug prescriptions
as well as patient referrals and hospital admissions in the
GPRD, using standard coding systems. The GPs generate
prescriptions directly with the computer, and this informa-
tion is automatically transcribed into the individual com-
puterized patient profiles. Additionally, the GPRD holds
information regarding lifestyle variables such as body mass
index (BMI) and smoking. Recorded information on drug
exposure and diagnoses has been validated repeatedly and
has proven to be of high quality [31–33]. Patients enrolled in
the GPRD are representative of the UK with regard to age,
gender, and geographic distribution, currently covering
about 7 % of the UK population. GPRD is managed by the
medicines and healthcare products regulatory agency
(MHRA) in the UK. The study protocol was reviewed and
approved by the Independent Scientific Advisory Commit-
tee for MHRA database research (ISAC). The investigators
had only access to anonymized information.
Study population
The study base population included all patients in the GPRD
between 40 and 89 years of age from 1 January 1994 to 31
October 2010. Cases were all persons in the study base
population who had an incident diagnosis of esophageal
cancer recorded during the study period. The date of this
first recorded diagnosis for esophageal cancer will be
referred to as ‘‘index date.’’ We excluded all patients with a
recorded diagnosis of HIV, alcoholism, or any malignancy
prior to the index date. All cases were required to have a
minimum of 3 years of medical history in the GPRD
computer record prior to the index date. From the base
population, up to 10 controls without any evidence of
esophageal cancer were identified at random for each case
with esophageal cancer, matched on calendar time (same
index date), age, sex, general practice, and number of years
of active history in the GPRD prior to the index date. The
same exclusion criteria were applied to controls as to cases.
Exposure to metformin or other anti-diabetic agents
We identified from the computer records all prescriptions
for insulin and oral anti-diabetic drugs (metformin, sulfo-
nylureas, thiazolidinediones, glinides, and glucosidase
inhibitors) prior to the index date. We defined several
exposure levels based on the recorded number of prescrip-
tions prior to the index date and classified patients by type of
anti-diabetic treatment and by duration of use: short-term
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(1–14 prescriptions), medium-term (15–29 prescriptions), or
long-term (C30 prescriptions) use. Additionally, we looked
at time since first prescription of an anti-diabetic drug.
Glucosidase inhibitors and prandial glucose regulators (gli-
nides) were not included in the final multivariate model,
because exposure to these drugs was low.
We compared use of anti-diabetic drugs to nonuse, and
use of more than one anti-diabetic drug was possible. We
then adjusted for sequential or concurrent use of various
anti-diabetic drugs in the multivariate models.
Statistical analysis
We conducted conditional logistic regression analyses
using the SAS statistical software version 9.3 (SAS Insti-
tute Inc, Cary, NC) to calculate relative risk estimates as
ORs with 95 % confidence intervals (CIs) and considered a
2-sided p value of \0.05 as statistically significant. In the
main analysis, the index date was shifted back by 2 years
in time both for cases and controls (i.e., we assessed all
exposure and covariate information from the day 2 years
immediately preceding the index date). This was done to
take into account the latency of the disease. We controlled
for the potential confounders age, sex, general practice,
calendar time, and years of recorded history in the database
by matching, and for smoking status (never, ex-smoker,
current, or unknown) and BMI (\25, 25–29.9, C 30 kg/m2)
in the multivariate model. Additionally, we explored the
association between various potential confounders and the
risk of esophageal cancer in univariate analyses including
alcohol consumption, comorbidities such as diabetes mel-
litus, gastro-esophageal reflux disease (GERD), congestive
heart failure, ischemic heart disease, ischemic or hemor-
rhagic stroke, arterial hypertension, and dyslipidemia and
exposure to antacid drugs, nonsteroidal anti-inflammatory
drugs (NSAIDs), acetylsalicylic acid, estrogens, and bis-
phosphonates. Since these variables did not alter the rela-
tive risk estimates for the association between use of anti-
diabetic drugs and the risk of esophageal cancer by more
than 10 %, they were not included in the final multivariate
analyses. Metformin has been associated with an increased
risk of lactic acidosis in patients with certain cardiovas-
cular comorbid conditions as well as renal disease. This
could, in theory, have led to channeled prescribing of
metformin to only those patients without the mentioned
comorbidities. We therefore compared metformin use in
cases and controls with and without these conditions.
However, metformin was not less prescribed in patients
with comorbid cardiovascular conditions.
In pre-specified sensitivity analyses, we only included
cases with esophageal cancer followed by codes for
radiotherapy, chemotherapy, surgery for esophageal carci-
noma, or specific oncology codes, in order to reduce the
risk of potential misclassification of cancer cases. As dia-
betes has been shown to be associated with an increased
cancer risk in several previous studies, we assessed the risk
of esophageal cancer in association with anti-diabetic drug
use in a population sample restricted to diabetic patients
and controls. For this sensitivity analysis, we additionally
analyzed time since diabetes diagnosis and HbA1c level (as
a proxy of diabetes control).
Furthermore, as certain risk factors have been shown to
have a different effect on the risk of esophageal cancer
depending on the histology (adenocarcinoma vs squamous
cell carcinoma), we searched the patient records for
information about the histology of the diagnosed tumor and
attempted to perform stratified analyses according to the
histological type of esophageal cancer.
Results
We identified a total of 3,819 cases with incident cancer of
the esophagus and 38,190 matched controls. Almost two-
thirds of cases were men (64.5 %). The mean (± SD) age
of cases and controls was 69.1 (± 11.0) years at the index
date. Detailed characteristics of cases and controls are
displayed in Table 1. The duration of history recorded in
the GPRD before the cancer diagnosis ranged from
5–21.8 years in cases and 3–21.9 years in controls, the
median of 11.6 years did not differ between cases and
controls. A record of radiotherapy or chemotherapy, an
oncology code, or esophagus-related surgery was available
for 74.3 % of the cancer cases after the cancer diagnosis.
The risk for esophageal cancer was increased for current
smokers compared with nonsmokers (crude OR 1.89, 95 %
CI 1.72–2.07). Obesity (BMI of C 30 kg/m2) was associ-
ated with a slightly increased risk for esophageal cancer in
the subgroup with a recorded histology for adenocarcinoma
(crude OR 1.43, 95 % CI 1.08–1.91) but not in the sub-
group with squamous cell carcinoma (crude OR 0.64, 95 %
CI 0.38–1.06).
Exposure to some drug groups was associated with a
slightly altered esophageal cancer risk in univariate anal-
yses (Table 1), but did not affect the results of the multi-
variate analyses. A diagnosis of diabetes was associated
with a marginally increased risk of esophageal cancer
(crude OR 1.13, 95 % CI 1.01–1.27). A long-lasting dia-
betes history of [ 10 years yielded a crude OR of 1.23
(95 % CI 0.90–1.67), compared to patients who had dia-
betes for less than 2 years. The time since the first diag-
nosis of diabetes was similar for cases and controls in the
three categories of metformin exposure. High HbA1c levels
within the last 3 years before the index date were also
associated with a slightly, but statistically not significantly
increased risk for esophageal cancer (crude OR 1.36, 95 %
Cancer Causes Control (2013) 24:1763–1770 1765
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Table 1 Characteristics of patients with esophageal cancer and controls
Cases (%) (n = 3,819) Controls (%) (n = 38,190) Crude OR (95 % CI) p value
Age (years)
40–59 810 (21.2) 8,133 (21.3) –
60–69 1,000 (26.2) 9,914 (26.0) –
70–79 1,263 (33.1) 12,770 (33.4) –
C 80 746 (19.5) 7,373 (19.3) –
Sex
Male 2,463 (64.5) 24,630 (64.5) –
Female 1,356 (35.5) 13,560 (35.5) –
Smoking
Nonsmoker 1,335 (35.0) 16,393 (42.9) 1.00 (referent)
Current 849 (22.2) 5,709 (15.0) 1.89 (1.72–2.07) \.0001
Past 1,067 (27.9) 9,800 (25.7) 1.38 (1.26–1.51) \.0001
Unknown 568 (14.9) 6,288 (16.5) 1.10 (0.98–1.22) 0.1046
BMI
\25 1,071 (28.0) 10,853 (28.4) 1.00 (referent)
25–29.9 1,170 (30.6) 12,301 (32.2) 0.96 (0.88–1.05) 0.4145
C30 624 (16.3) 5,471 (14.3) 1.16 (1.04–1.29) 0.0058
Unknown 954 (25.0) 9,565 (25.1) 1.01 (0.92–1.11) 0.8549
Alcohol use
Never 570 (14.9) 5,328 (14.0) 1.00 (referent)
Current 2,338 (61.2) 23,307 (61.0) 0.93 (0.84–1.03) 0.1785
Past 43 (1.1) 444 (1.2) 0.90 (0.65–1.26) 0.5477
Unknown 868 (22.7) 9,111 (23.9) 0.88 (0.78–0.99) 0.0291
Comorbidities
CHF 174 (4.6) 1,402 (3.7) 1.27 (1.07–1.50) 0.0050
IHD 585 (15.3) 5,864 (15.4) 1.00 (0.91–1.10) 0.9504
Hypertension 1,335 (35.0) 13,458 (35.2) 0.99 (0.92–1.06) 0.7134
Stroke/TIA 260 (6.8) 2,661 (7.0) 0.98 (0.85–1.12) 0.7090
Dyslipidemia 445 (11.7) 4,961 (13.0) 0.87 (0.78–0.97) 0.0134
Diabetes 370 (9.7) 3,325 (8.7) 1.13 (1.01–1.27) 0.0390
GERD 557 (14.6) 4,316 (11.3) 1.36 (1.24–1.50) \.0001
Barrett’s esophagus 107 (2.8) 162 (0.4) 6.85 (5.34–8.78) \.0001
Achalasia 12 (0.3) 19 (0.05) 6.49 (3.12–13.49) \.0001
Hiatus hernia 312 (8.2) 2,066 (5.4) 1.58 (1.39–1.79) \.0001
NSAIDs
No prior use 1,756 (46.0) 16,837 (44.1) 1.00 (ref)
1–4 Rx 1,164 (30.5) 11,885 (31.1) 0.93 (0.86–1.01) 0.0818
C5 Rx 899 (23.5) 9,468 (24.8) 0.90 (0.82–0.98) 0.0188
Estrogens (women only)
No prior use 1,157 (85.3) 11,296 (83.3) 1.00 (ref)
1–9 Rx 90 (6.6) 1,050 (7.7) 0.81 (0.64–1.02) 0.0746
C10 Rx 109 (8.0) 1,214 (9.0) 0.84 (0.67–1.05) 0.1260
Bisphosphonates
No prior use 3,659 (95.8) 36,955 (96.8) 1.00 (ref)
1–9 Rx 63 (1.7) 581 (1.5) 1.12 (0.86–1.46) 0.4140
C10 Rx 97 (2.5) 654 (1.7) 1.54 (1.23–1.93) \.0001
PPIs
No prior use 2,913 (76.3) 30,599 (80.1) 1.00 (ref)
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CI 0.95–1.95). We included the variables ‘‘time since first
diagnosis of diabetes mellitus’’ and ‘‘HbA1c level’’ in the
multivariate model, which was restricted to diabetic
patients only.
Long-term use of metformin (C 30 prescriptions) was
not associated with a materially altered risk of esophageal
cancer in the main analysis (adj. OR 1.23, 95 % CI
0.92–1.65) or in the analysis restricted to diabetic patients
(adj. OR 1.31, 95 % CI 0.93–1.85) (Table 2). When we
restricted the analysis to cases with recorded radiotherapy,
chemotherapy, oncology codes, or surgery after the cancer
diagnosis, the finding for long-term users of metformin was
closely similar to the result from the main analysis (adj. OR
1.31, 95 % CI 0.94–1.82). Analyses stratified according to
age or sex did not reveal differing relative cancer risks for
metformin users (p value for effect modification [0.05).
Furthermore, the analysis according to time since first
prescription for an anti-diabetic drug yielded similar results
compared to the main analysis (adj. OR for metformin use
with a first prescription [ 5 years before the cancer diag-
nosis compared with no metformin use was 1.11, 95 % CI
0.79–1.54).
Neither use of sulfonylureas, insulin, or thiazolidinedi-
ones was associated with an altered risk of esophageal
cancer in the main analysis or in the analysis restricted to
diabetic patients (Table 2).
Only very few codes indicating adenocarcinoma (13 %
of the cancer cases) or squamous cell carcinoma (4.7 % of
the cancer cases) were found in the patient records. Con-
sequently, exposure to antidiabetic drugs within patients
with available information on cancer histology was too low
to report any meaningful results.
Discussion
This population-based study on the risk of esophageal
cancer and use of anti-diabetic drugs did not provide evi-
dence for an association between metformin and the risk of
esophageal cancer. The results were similar in various
subgroups of patients and in predefined sensitivity analy-
ses. To our knowledge, to date, there is only one study in
the literature that has reported an association between use
of metformin and esophageal cancer [22]. In this cohort
study, ever use of metformin compared with use of other
oral anti-diabetic drugs yielded an adjusted hazard ratio of
0.44 (95 % CI 0.07–2.61) in one statistical model, based on
only 21 exposed cases and 6 exposed controls. Of note, in
additional analyses, HRs markedly differed according to
the covariates included in the model (HRs of 1.15, 95 % CI
0.46–2.84 and 1.27, 95 % CI 0.51–3.16, respectively, for
esophageal cancer in metformin users). Additionally, the
patient population of this study consisted mainly of Asians
while we predominantly studied Caucasians.
Our results are in line with observations from previous
studies on the risk factors for esophageal cancer. We report
an increased risk of esophageal cancer in current smokers,
and smoking was reported to increase the risk of both
adenocarcinoma and squamous cell carcinoma in a recent
analysis of pooled data from 12 case–control studies [34].
Our observation on the increased cancer risk associated
with obesity in cases of adenocarcinoma of the esophagus
is also consistent with earlier findings [35, 36]. Further-
more, the risk of esophageal cancer in patients from our
study with ten or more prescriptions of a bisphosphonate
(1.54, 95 % CI 1.23–1.93) lies within the confidence limits
of both previous studies, investigating bisphosphonate use
and esophageal cancer risk with GPRD data [37, 38].
Several limitations to our study need to be acknowl-
edged. First, misclassification of cancer diagnoses may be
present to some degree as we did not review original
medical records for esophageal cancer cases. However,
esophageal cancer is a reliable diagnosis in the GPRD, as
shown by a recent study including chart review of 895
female esophageal cancer patients [39]. In that sample,
92 % of the cases with a recorded diagnosis of esophageal
cancer were shown to have a valid diagnosis. We were not
able to adjust for socioeconomic status (SES) or diet, two
potential risk factors common to both cancer and diabetes
[12]. However, by matching on general practice and
Table 1 continued
Cases (%) (n = 3,819) Controls (%) (n = 38,190) Crude OR (95 % CI) p value
1–14 Rx 510 (13.4) 5,052 (13.2) 1.08 (0.98–1.20) 0.1226
C15 Rx 396 (10.4) 2,539 (6.7) 1.71 (1.52–1.92) \.0001
H2-antihistaminergic drugs
No prior use 3,011 (78.8) 30,916 (81.0) 1.00 (ref)
1–14 Rx 577 (15.1) 5,288 (13.9) 1.13 (1.03–1.24) 0.0133
C15 Rx 231 (6.1) 1,986 (5.2) 1.21 (1.05–1.39) 0.0105
CHF Congestive heart failure, CI Confidence interval, GERD Gastro-esophageal reflux disease, IHD Ischemic heart disease, OR Odds ratio,
TIA Transient ischemic attack, NSAID Nonsteroidal anti-inflammatory drugs, PPIs Proton-pump inhibitors
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thereby on community, we aimed at minimizing potential
confounding by SES and by related variables. Moreover, a
recent study from Scotland did not show an association
between socioeconomic inequalities and esophageal cancer
risk [40]. Furthermore, we were not able to differentiate
between cases with different cancer histology in the
majority of our patient sample, and the number of indi-
viduals with known histology who were exposed to anti-
diabetic drugs was too small to confer any meaningful
interpretation regarding esophageal cancer risk for histo-
logical subgroups. Finally, we might have missed a pro-
tective effect of metformin due to limited exposure
duration of roughly 5 years in patients with C30 pre-
scriptions of metformin. However, since we did not
observe any trend toward a decreased risk of esophageal
cancer among prescription categories of metformin in this
study, such an effect seems to be rather unlikely.
There are several strengths of our study. First, we were
able to study a large number of patients with a recorded
diagnosis of esophageal cancer in a well-established primary
care database of high quality and completeness. All infor-
mation on drug use and disease diagnoses was recorded
prospectively, eliminating the possibility of recall bias.
Additionally, we were able to evaluate in our analyses
several potential confounders such as BMI, smoking habits,
as well as comorbid conditions and prescriptions of other
drugs. Furthermore, by excluding all patients with less than
3 years of recorded history in the database before the index
date, we reduced the risk of including prevalent rather than
incident cancer cases. Cases and controls had a comparable
duration of diabetes in each metformin exposure category.
This speaks against the presence of different time windows
of exposure opportunity (time-window bias) in cases and
controls. At last, shifting the index date by 2 years back-
wards in time increased the likelihood that exposure to anti-
diabetic drugs preceded the development of esophageal
cancer, thus avoiding any protopathic bias (a drug being
prescribed for an early manifestation of a disease that has
not yet been diagnosed); it also accounted for the latency
period of clinically detectable esophageal cancer.
In conclusion, in our population-based study, we did not
find evidence for an altered risk of esophageal cancer
in association with use of metformin or other anti-diabetic
drugs.
Table 2 Risk of cancer of the esophagus and number of prescriptions for anti-diabetic drug in cases and controls
Drugs and No.
prescriptions
All patients Diabetic patients only
Cases (%)
(n = 3,819)
Controls (%)
(n = 38,190)
Adjusted ORa
(95 % CI)
p value Cases (%)
(n = 370)
Controls (%)
(n = 3,700)
Adjusted ORb
(95 % CI)
p value
Metformin
No prior use 3,621 (94.8) 36,505 (95.6) 1.00 (referent) 173 (46.8) 1,857 (50.2) 1.00 (referent)
1–14 63 (1.7) 561 (1.5) 0.99 (0.74–1.33) 0.9482 62 (16.8) 668 (18.1) 0.95 (0.68–1.33) 0.7678
15–29 43 (1.1) 385 (1.0) 1.01 (0.71–1.43) 0.9768 43 (11.6) 433 (11.7) 1.02 (0.69–1.50) 0.9317
C30 92 (2.4) 739 (1.9) 1.23 (0.92–1.65) 0.1634 92 (24.9) 742 (20.1) 1.31 (0.93–1.85) 0.1280
Sulfonylureas
No prior use 3,618 (94.7) 36,471 (95.5) 1.00 (referent) 171 (46.2) 1,915 (51.8) 1.00 (referent)
1–14 59 (1.5) 430 (1.1) 1.33 (0.99–1.80) 0.0623 58 (15.7) 460 (12.4) 1.31 (0.94–1.83) 0.1074
15–29 47 (1.2) 375 (1.0) 1.16 (0.83–1.64) 0.3810 46 (12.4) 363 (9.8) 1.29 (0.89–1.87) 0.1847
C30 95 (2.5) 914 (2.4) 0.93 (0.70–1.23) 0.6064 95 (25.7) 962 (26.0) 0.86 (0.62–1.21) 0.3873
Insulin
No prior use 3,752 (98.3) 37,585 (98.4) 1.00 (referent) 303 (81.9) 3,033 (82.0) 1.00 (referent)
1–14 18 (0.5) 145 (0.4) 1.04 (0.62–1.73) 0.8841 18 (4.9) 147 (4.0) 1.05 (0.62–1.76) 0.8674
15–29 14 (0.4) 110 (0.3) 1.09 (0.61–1.94) 0.7683 14 (3.8) 131 (3.5) 0.90 (0.50–1.62) 0.7139
C30 35 (0.9) 350 (0.9) 0.87 (0.60–1.25) 0.4475 35 (9.5) 389 (10.5) 0.71 (0.47–1.08) 0.1133
TZD
No prior use 3,783 (99.1) 37,902 (99.3) 1.00 (referent) 335 (90.5) 3,397 (91.8) 1.00 (referent)
1–14 25 (0.7) 158 (0.4) 1.38 (0.88–2.18) 0.1627 24 (6.5) 185 (5.0) 1.19 (0.74–1.92) 0.4813
C15 11 (0.3) 130 (0.3) 0.71 (0.37–1.36) 0.3019 11 (3.0) 118 (3.2) 0.82 (0.42–1.60) 0.5592
OR Odds ratio, CI Confidence interval, TZD Thiazolidinediones
a all patients adjusted for all other medications in this table, BMI, and smoking
b diabetic patients only; adjusted for each other, BMI, smoking, diabetes duration, and HbA1c level
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